Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires Shares of 18,000 CareDx, Inc. $CDNA
04:36am, Sunday, 26'th Oct 2025
VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in CareDx, Inc. (NASDAQ: CDNA) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor a
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differenti
CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors
04:01pm, Wednesday, 22'nd Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiate
CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025
08:00am, Tuesday, 21'st Oct 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercializ
CareDx Issues Comment Letter on Draft LCD Policy
04:01pm, Tuesday, 02'nd Sep 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential
01:08pm, Tuesday, 26'th Aug 2025
CareDx, Inc. CDNA faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company's expanding transplant solutions platform
CareDx to Participate in Wells Fargo Healthcare Conference
04:01pm, Thursday, 21'st Aug 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of cl
CareDx (CDNA) EPS Beats Sales Gain 14%
11:42pm, Wednesday, 06'th Aug 2025
CareDx (CDNA) EPS Beats Sales Gain 14%
CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript
10:47pm, Wednesday, 06'th Aug 2025
CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant Jo
Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings
07:32pm, Wednesday, 06'th Aug 2025
The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates
06:45pm, Wednesday, 06'th Aug 2025
CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
04:57pm, Wednesday, 06'th Aug 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
CareDx Announces Second Quarter 2025 Financial Results
04:01pm, Wednesday, 06'th Aug 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinical
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
12:56pm, Wednesday, 06'th Aug 2025
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
